The one area where a cannabinoid crossed the full distance: anecdote → controlled trials → approved medicine.
Epidiolex (purified CBD) won FDA and EMA approval for Dravet syndrome, Lennox-Gastaut syndrome and tuberous sclerosis complex after randomized placebo-controlled trials showed meaningful seizure reductions. This is the gold-standard path, completed.
CBD epilepsy trials — PubMed ↗Median convulsive-seizure reductions in the pivotal trials ran around 40–50% versus ~15–25% on placebo. Life-changing for many families, but "reduction", not "cure", is the honest frame.
Seizure reduction magnitude — PubMed ↗Trial results come from a standardized pharmaceutical preparation at 10–20 mg/kg/day. Market CBD products vary wildly in actual content and deliver far lower doses — families substituting them for Epidiolex are not running the same experiment.
CBD product content variability — PubMed ↗The completed trials concentrate on severe pediatric syndromes. Evidence for CBD in common adult focal epilepsy is promising but not yet approval-grade; trials are ongoing.
CBD adult focal epilepsy — PubMed ↗Purified CBD (Epidiolex) is FDA- and EMA-approved for Dravet syndrome, Lennox-Gastaut syndrome and TSC-related seizures, cutting seizure frequency in randomized controlled trials. This is the gold standard of cannabinoid evidence: real RCTs, real approval.
CBD STRONG EVIDENCEIn the Epidiolex epilepsy trials, a meaningful share of patients on high-dose CBD (10–20 mg/kg/day) showed elevated liver transaminases, especially with valproate. This is why the label requires liver monitoring — and why megadose self-experimentation is not harmless.
CBD STRONG EVIDENCEHuman studies showing CBD effects typically use 300–600 mg per day, sometimes more. Over-the-counter products commonly suggest 5–25 mg. Whatever you believe about CBD's potential, most consumer products deliver a small fraction of studied doses — expectations should scale accordingly.
CBD STRONG EVIDENCEDronabinol and nabilone (synthetic THC) are approved for chemo nausea and AIDS wasting; nabiximols (THC+CBD spray) is approved for MS spasticity in 25+ countries; Epidiolex (CBD) for severe epilepsy. The medical channel exists and works — it is simply narrower than the dispensary menu suggests.
Medical EvidenceCannabis is not an approved treatment for epilepsy in most jurisdictions, and nothing here recommends using it. If epilepsy affects your life, bring this research — literally, these sources — to a physician and decide together. Laws differ by country and state; check CannabisLaws.ai before anything else.